BeyondSpring Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.83
- Today's High:
- $0.929
- Open Price:
- $0.9006
- 52W Low:
- $0.542
- 52W High:
- $3.45
- Prev. Close:
- $0.929
- Volume:
- 112305
Company Statistics
- Market Cap.:
- $51.77 million
- Book Value:
- -0.153
- Revenue TTM:
- $1.35 million
- Operating Margin TTM:
- -2756.4%
- Gross Profit TTM:
- $1.35 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -36.4%
- Return on Equity TTM:
- -310.48%
Company Profile
BeyondSpring Inc had its IPO on 2017-03-09 under the ticker symbol BYSI.
The company operates in the Healthcare sector and Biotechnology industry. BeyondSpring Inc has a staff strength of 73 employees.
Stock update
Shares of BeyondSpring Inc opened at $0.9 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.83 - $0.93, and closed at $0.93.
This is a 0% increase from the previous day's closing price.
A total volume of 112,305 shares were traded at the close of the day’s session.
In the last one week, shares of BeyondSpring Inc have slipped by -2.21%.
BeyondSpring Inc's Key Ratios
BeyondSpring Inc has a market cap of $51.77 million, indicating a price to book ratio of 1.6777 and a price to sales ratio of 62.2401.
In the last 12-months BeyondSpring Inc’s revenue was $1.35 million with a gross profit of $1.35 million and an EBITDA of $-37007000. The EBITDA ratio measures BeyondSpring Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, BeyondSpring Inc’s operating margin was -2756.4% while its return on assets stood at -36.4% with a return of equity of -310.48%.
In Q1, BeyondSpring Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 0.1%.
BeyondSpring Inc’s PE and PEG Ratio
- Forward PE
- 10.5374
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-1.14 per share while it has a forward price to earnings multiple of 10.5374 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into BeyondSpring Inc’s profitability.
BeyondSpring Inc stock is trading at a EV to sales ratio of 5.269 and a EV to EBITDA ratio of 0.3725. Its price to sales ratio in the trailing 12-months stood at 62.2401.
BeyondSpring Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $0
- Total Liabilities
- $0
- Operating Cash Flow
- $0
- Capital Expenditure
- $2.84 million
- Dividend Payout Ratio
- 0%
BeyondSpring Inc ended 2024 with $0 in total assets and $0 in total liabilities. Its intangible assets were valued at $0 while shareholder equity stood at $0.
BeyondSpring Inc ended 2024 with $0 in deferred long-term liabilities, $0 in other current liabilities, in common stock, $0 in retained earnings and $0 in goodwill. Its cash balance stood at $0 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
BeyondSpring Inc’s total current assets stands at $0 while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $0 and inventory worth $0.
In 2024, BeyondSpring Inc's operating cash flow was $0 while its capital expenditure stood at $2.84 million.
Comparatively, BeyondSpring Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.93
- 52-Week High
- $3.45
- 52-Week Low
- $0.542
- Analyst Target Price
- $1.13
BeyondSpring Inc stock is currently trading at $0.93 per share. It touched a 52-week high of $3.45 and a 52-week low of $3.45. Analysts tracking the stock have a 12-month average target price of $1.13.
Its 50-day moving average was $1.02 and 200-day moving average was $1.35 The short ratio stood at 22.97 indicating a short percent outstanding of 0%.
Around 3057.9% of the company’s stock are held by insiders while 1546.9% are held by institutions.
Frequently Asked Questions About BeyondSpring Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company’s lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.